Portfolio mapping & regulatory signals

Start from a roster—or from a single ingredient.

Upload products when you have a catalog. Search one substance when you do not. Both routes use the same scored signals; portfolio assessment and Ingredient diligence stay distinct.

  • Portfolio risk concentration
  • Per-product exposure & ownership
  • Scored signals with origin context

Two entry paths

Roster upload or ingredient search

Two entry paths, one workspace: structured signals with provenance, optional portfolio mapping with owners, and optional Ingredient diligence drafts for human review.

I have a roster

Operators run intake and validation; assessment joins products to signals for exposure and ownership—leadership sees concentration, teams work the rows.

Portfolio intake

Canonical product record

Signal generation

Portfolio assessment

Dashboards & handoff

I have an ingredient

No roster required. Resolve a substance, inspect corpus and signal evidence, then draft an Ingredient diligence brief for human review. This is not M&A diligence and not legal advice.

Search & resolve

Products, signals, jurisdictions

Ingredient diligence draft

Governance & access

Signals stay tied to evidence; ingredient research needs no roster; portfolio impact stays owned—built for operator review, not opaque alerts.

Start with individual usage-based access when you are ready. Enterprise teams use institutional onboarding with fit and governance review.

  • Human-in-the-loop review stays in operator workflows.
  • Recommendations remain evidence-linked and auditable.
  • Portfolio mapping is role-aware with explicit ownership.